alpha-10/beta-1 integrin inhibitors (Xintela)

N/A

Report date: 2025/03/14 16:54:10

Base Information

Drug Namealpha-10/beta-1 integrin inhibitors (Xintela)
Drug Alias Namealpha-10/beta-1 integrin-inhibitors (Hansa Medical)alpha-10/beta-1 integrin-inhibitors (Xintela)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody
Mechanisms of ActionIntegrin alpha10/beta1 antagonists
TargetsIntegrin alpha10/beta1
Therapy Area/IndicationsCartilage DiseasesCentral Nervous System NeoplasmsTriple Negative Breast Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySweden
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesHansa Biopharma Ab
China Registration ClassN/A

Develop Information

Active CompaniesXintela AB
Inactive CompaniesHansa Biopharma Ab
Active IndicationsCentral Nervous System NeoplasmsTriple Negative Breast NeoplasmsGlioblastoma
Inactive IndicationsCartilage Diseases

Other Information

ATC CodeN/A
Related LinksN/A